• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Biotech

    FibroGen Rebrands as Kyntra Bio, Signaling Fresh Momentum

    GLOBENEWSWIRE

    FibroGen to Report Third Quarter 2025 Financial Results

    GLOBENEWSWIRE

    Fibrogen Start Ph2 Trial Of Fg-3246 In Metastatic Prostate Cancer

    GLOBENEWSWIRE

    FibroGen Pays SEC $1.2M for `Reverse Engineered` Data Claims

    FIERCE PHARMA

    FibroGen Reveals Q2 2025 Financial Results and Business Update

    GLOBENEWSWIRE

    FibroGen Gets FDA Type C Meeting Win for Roxadustat in MDS

    GLOBENEWSWIRE

    FibroGen to Report Q4 and Full Year 2024 Financial Results

    GLOBENEWSWIRE

    FibroGen Sells China Business To AstraZeneca For $160M

    GLOBENEWSWIRE

    FibroGen Reports Q3 2024 Financial Results

    GLOBENEWSWIRE

    FibroGen to Report Q3 2024 Financial Results

    GLOBENEWSWIRE

    FibroGen Reports Q2 2024 Results And Provides Business Update

    GLOBENEWSWIRE

    FibroGen Reports Pamrevlumab Pancreatic Cancer Study Results

    GLOBENEWSWIRE

    Fibrogen Fg-3246 Interim Phase 1b: Mcrpc Positive With Enzalutamide

    GLOBENEWSWIRE

    FibroGen`s FG-3246 + Enzalutamide Data at ASCO 2024

    GLOBENEWSWIRE

    Prostate cancer ADC breaks FibroGen`s clinical losing streak

    FIERCE BIOTECH

    FibroGen Announces Results from Ph 1 of FG-3246 for Prostate Cancer

    GLOBENEWSWIRE

    FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise

    GLOBENEWSWIRE

    FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab

    GLOBENEWSWIRE

    FibroGen Announces Results from LELANTOS-1 Phase 3 Study of Pamrevlumab

    PRESS RELEASE

    FibroGen snags sole ADC asset from small biotech for $280M

    FIERCE BIOTECH

    FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics

    GLOBENEWSWIRE

    Astellas depreciates FibroGen`s Evrenzo, nixes cell therapy deal

    FIERCE PHARMA

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.